P L Mai

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma
    Phuong L Mai
    Clinical Genetic Branch, National Cancer Institute, Rockville, Maryland, United States of America
    PLoS ONE 4:e4812. 2009
  2. doi request reprint Awareness of cancer susceptibility genetic testing: the 2000, 2005, and 2010 national health interview surveys
    Phuong L Mai
    Division of Cancer Epidemiology and Genetics, NIH, Bethesda, Maryland Electronic address
    Am J Prev Med 46:440-8. 2014
  3. pmc Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium
    Phuong L Mai
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Genet 205:479-87. 2012
  4. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  5. pmc Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer
    Christine M Mueller
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    BMC Complement Altern Med 8:17. 2008
  6. pmc Confirmation of family cancer history reported in a population-based survey
    Phuong L Mai
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7022, Rockville Pike, Bethesda, MD 20852, USA
    J Natl Cancer Inst 103:788-97. 2011
  7. pmc Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study
    P L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
    Public Health Genomics 13:495-503. 2010
  8. pmc A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report
    Phuong L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Med Case Reports 1:9. 2007
  9. pmc Younger age-at-diagnosis for familial malignant testicular germ cell tumor
    Phuong L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MA 20852, USA
    Fam Cancer 8:451-6. 2009
  10. pmc The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred
    Phuong L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
    Urol Oncol 28:492-9. 2010

Collaborators

Detail Information

Publications15

  1. pmc Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma
    Phuong L Mai
    Clinical Genetic Branch, National Cancer Institute, Rockville, Maryland, United States of America
    PLoS ONE 4:e4812. 2009
    ..Further, possible effect of BRCA mutations on non-cancer mortality risk has not been examined...
  2. doi request reprint Awareness of cancer susceptibility genetic testing: the 2000, 2005, and 2010 national health interview surveys
    Phuong L Mai
    Division of Cancer Epidemiology and Genetics, NIH, Bethesda, Maryland Electronic address
    Am J Prev Med 46:440-8. 2014
    ..Genetic testing for several cancer susceptibility syndromes is clinically available; however, existing data suggest limited population awareness of such tests...
  3. pmc Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium
    Phuong L Mai
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Genet 205:479-87. 2012
    ..This workshop also led to the creation of the Li-Fraumeni Exploration (LiFE) Research Consortium...
  4. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  5. pmc Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer
    Christine M Mueller
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    BMC Complement Altern Med 8:17. 2008
    ..Complementary and alternative medicine (CAM) use is well documented among breast cancer patients and survivors, but little evidence is available to describe rates and patterns of use among women at increased genetic risk of breast cancer...
  6. pmc Confirmation of family cancer history reported in a population-based survey
    Phuong L Mai
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7022, Rockville Pike, Bethesda, MD 20852, USA
    J Natl Cancer Inst 103:788-97. 2011
    ..However, it is not clear if reported family cancer history is sufficiently accurate for this purpose...
  7. pmc Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study
    P L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
    Public Health Genomics 13:495-503. 2010
    ..A positive family history is a known risk factor for several cancers; thus, obtaining a thorough family cancer history is essential in cancer risk evaluation and prevention management...
  8. pmc A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report
    Phuong L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Med Case Reports 1:9. 2007
    ..Familial testicular cancer in the presence of other findings in affected and unaffected family members might indicate a previously-unidentified hereditary cancer syndrome...
  9. pmc Younger age-at-diagnosis for familial malignant testicular germ cell tumor
    Phuong L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MA 20852, USA
    Fam Cancer 8:451-6. 2009
    ..The younger age at diagnosis might be suggestive of a genetic basis for familial TGCT...
  10. pmc The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred
    Phuong L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
    Urol Oncol 28:492-9. 2010
    ..Here we describe a collection of familial TGCT cases from an international consortium, in an effort to elucidate any clinical characteristics that are specific to this population...
  11. pmc Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment
    Phuong L Mai
    Department of Clinical Cancer Genetics, City of Hope National Medical Center, Duarte, CA, USA
    Ann Surg Oncol 15:3415-21. 2008
    ..In this study, we examined the use of CRRM before versus after genetic cancer risk assessment (GCRA) in women diagnosed with breast cancer before age 50...
  12. pmc Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype
    Mark H Greene
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852, USA
    Endocr Relat Cancer 17:R109-21. 2010
    ..All five loci are involved in normal testicular development and/or male infertility. These genetic data provide a novel insight into the genetic basis of FTGCT, and an invaluable guide to future TGCT research...
  13. pmc Challenges related to developing serum-based biomarkers for early ovarian cancer detection
    Phuong L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 4:303-6. 2011
    ....
  14. pmc A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study
    Mark H Greene
    Clinical Genetics Branch, National Cancer Institute, 6120 Executive Boulevard, Room EPS 7032, Rockville, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 17:594-604. 2008
    ..We developed a collaboration among the Clinical Genetics Branch (National Cancer Institute's Intramural Research Program), the Gynecologic Oncology Group (GOG), and the Cancer Genetics Network to address these issues...
  15. pmc Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer
    Gretchen L Gierach
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Office of Preventive Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Breast Cancer Res Treat 123:245-55. 2010
    ..Taking these factors into account did not significantly alter the results of the age/body mass index-adjusted analysis. Our results do not provide support for an independent effect of BRCA1/2 mutation status on mammographic density...